Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Conference research case study

How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event

Portfolio analysis: Using market research to master communications across a therapeutic category

Many of us are familiar with billiard games, where two players compete to be the first to pocket all the balls on the table in a particular order.  We recently...

EphMRA round up 2018

EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.

Patients’willingness to pay

Considerations when developing an appropriate pricing strategy in self-pay markets

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...

Shift to preventative healthcare – Opportunities for screening, diagnostics and vaccination

Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...

Conference Live for ongoing congress performance measurement

Director John Branston discusses the benefits of a mobile approach for evaluating medical conferences year-on-year

Eyeforpharma Real World Evidence Conference Round up 2018

Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)This year has seen a turning point...

PEGASUS SCOOPS TWO AWARDS AT COMMUNIQUÉ 2018 FOR ITS ‘SMALL TALK SAVES LIVES’ CAMPAIGN

Pegasus was also highly commended for Communiqué Agency of the Year 2018Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the Excellence In Public Health...